

This communication should be viewed by:
Facility/Practice staff

Pharmacy Policy Updates Effective December 1, 2026

MVP Health Care® (MVP) is notifying Providers of updated Pharmacy Policies, which can be viewed by visiting mvphealthcare.com/policies under the *Upcoming Policy Changes* section.

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2026, and will be available for viewing on or before November 1, 2026. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Effective December 1, 2026	
ACL Inhibitors	Updated
Etrasimod	Updated
Guselkumab (Tremfya)	Updated
Hemophilia Factor	Updated
Immunoglobulin Therapy	Updated
Irritable Bowel Syndrome	Reviewed/No Changes
Medicare Part B: Hemophilia Factor	Reviewed/No Changes
Medicare Part B: Immunoglobulin Therapy	Updated
Medicare Part B: Monoclonal Antibodies for Alzheimer's Disease	Updated
Monoclonal Antibodies for Alzheimer's Disease	Updated
Resmetirom	Reviewed/No Changes
Risankizumab (Skyrizi)	Updated
Risankizumab (Skyrizi) Part B	Updated
Secukinumab	Updated
Secukinumab Part B	Updated
Upadacitinib	Updated
Vedolizumab (formerly Entyvio)	Updated
Vedolizumab Part B (formerly Entyvio Part B)	Updated
Zycubo	New
Effective January 1, 2027	
Oral Allergen Immunotherapy Medications	Archived
Tofacitinib	Updated